Biotech News

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Immatics (IMTX)Immatics2026-05-30 12:00 ESTClinical readout

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR), 50% confirmed ORR (cORR), including four complete

Open original release

Related news

IMTXImmatics2026-06-01 12:00 EST

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

IMTXImmatics2026-05-31 13:00 EST

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

IMTXImmatics2026-04-21 14:26 EST

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

IMTXImmatics2026-04-17 19:00 EST

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

IMTXImmatics2026-03-05 12:00 EST

Immatics Announces Full Year 2025 Financial Results and Business Update

IMTXImmatics2025-12-11 12:00 EST

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

IMTXImmatics2025-12-05 11:01 EST

Immatics Announces $125 Million Underwritten Offering

IMTXImmatics2025-11-17 12:00 EST

Immatics Announces Third Quarter 2025 Financial Results and Business Update

IMTXImmatics2025-11-12 12:00 EST

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

View all latest news

Immatics

Immatics is an immunotherapy company focused on T-cell receptor science and cancer immunotherapies. The company is building a platform around targeted immune recognition in oncology.

Recent company news

IMTXBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

IMTXQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

IMTXMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

IMTXAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

IMTXGSK plc2026-07-22 11:21 EST

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Stock data

Close: 9.29 USD
Market cap: 1.37B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States